Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Notes Payables (2021 - 2023)

Avalo Therapeutics (AVTX) has disclosed Notes Payables for 3 consecutive years, with $14.1 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Notes Payables changed N/A year-over-year to $14.1 million, compared with a TTM value of $14.1 million through Jun 2023, changed N/A, and an annual FY2022 reading of $5.9 million, changed N/A over the prior year.
  • Notes Payables was $14.1 million for Q2 2023 at Avalo Therapeutics, up from $9.3 million in the prior quarter.
  • Across five years, Notes Payables topped out at $33.2 million in Q1 2022 and bottomed at $2.6 million in Q3 2022.
  • Average Notes Payables over 3 years is $16.4 million, with a median of $14.1 million recorded in 2023.
  • The sharpest move saw Notes Payables plummeted 92.11% in 2022, then tumbled 71.99% in 2023.
  • Year by year, Notes Payables stood at $32.5 million in 2021, then crashed by 81.74% to $5.9 million in 2022, then soared by 138.03% to $14.1 million in 2023.
  • Business Quant data shows Notes Payables for AVTX at $14.1 million in Q2 2023, $9.3 million in Q1 2023, and $5.9 million in Q4 2022.